利干德制药
LGND
295.54
-2.96
-0.99%
利干德制药
US · LGND
#1920 按市值排名
上市于 1970
295.54
-2.96
-0.99%
实时 - 追踪5344个代码 - 心跳于400秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了0.2个百分点。
机构持股
- 机构持股比例
- 115.80% -0.16pp
- 机构数量
- 477 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund108.00%
Public Company3.26%
Individual/Insider2.23%
Government Pension Fund1.74%
Hedge Fund1.38%
Private Company0.93%
Family Office/Trust0.28%
Insurance Company0.16%
主要股东 截至 2026-06-30
BlackRock
15.56% · 3.10M 股
Vanguard Portfolio Management, LLC
5.71% · 1.14M 股
Janus Henderson Group plc
5.22% · 1.04M 股
Vanguard Capital Management, LLC
5.09% · 1.01M 股
Invesco Ltd.
4.66% · 928.08K 股
State Street Global Advisors
4.15% · 826.54K 股
FMR
3.82% · 761.05K 股
Congress Asset Management Company, LLP
3.31% · 659.91K 股
Franklin Resources
2.98% · 593.09K 股
Geode Capital Management, LLC
2.95% · 589.02K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 18次买入 · 32次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Todd Davis | Chief Executive Officer | 0.82% |
| Jason Aryeh | Independent Director | 0.51% |
| John Kozarich | Independent Chairperson | 0.21% |
| Andrew Reardon | Chief Legal Officer | 0.18% |
| Stephen Sabba | Independent Director | 0.16% |
| Octavio Espinoza | Chief Financial Officer | 0.14% |
| John LaMattina | Independent Director | 0.13% |
| Nancy Gray | Independent Director | 0.04% |
| Jason Haas | Independent Director | 0.02% |
| Martine Zimmermann | Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-21 | Martine Zimmermann | Director | Sale to Issuer | -115 | $298.50 |
| 2026-09-09 | Martine Zimmermann | Director | Open Market Disposition | -1,200 | $285.00 |
| 2026-09-02 | Andrew Reardon | Chief Legal Officer | Automatic Disposition | -5,000 | $283.99–288.98 |
| 2026-08-11 | Jason Haas | Independent Director | Open Market Disposition | -1,000 | $292.81 |
| 2026-08-11 | Jason Haas | Independent Director | Derivative Exercise and Sale | -6,138 | $51.56–292.81 |
| 2026-08-11 | Octavio Espinoza | Chief Financial Officer | Derivative Exercise and Sale | -31,641 | $52.84–292.07 |
| 2026-08-02 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $52.27–292.82 |
| 2026-06-30 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $52.27–317.15 |
| 2026-06-29 | Todd Davis | Chief Executive Officer | Other Acquisition | +132 | $160.71 |
| 2026-06-29 | Andrew Reardon | Chief Legal Officer | Other Acquisition | +132 | $160.71 |
| 2026-06-29 | Octavio Espinoza | Chief Financial Officer | Other Acquisition | +17 | $160.71 |
| 2026-06-15 | Stephen Sabba | Independent Director | Derivative Exercise and Sale | -2,145 | $66.13–254.00 |
| 2026-06-11 | Jason Haas | Independent Director | Open Market Disposition | -2,461 | $256.08 |
| 2026-06-11 | Jason Haas | Independent Director | Derivative Exercise and Sale | -4,000 | $51.56–256.08 |
| 2026-06-10 | Jason Aryeh | Independent Director | Open Market Disposition | -5,000 | $250.00 |
| 2026-06-10 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -4,500 | $249.97 |
| 2026-06-09 | John LaMattina | Independent Director | Open Market Disposition | -4,591 | $247.22–251.62 |
| 2026-06-09 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -5,000 | $249.35 |
| 2026-06-09 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -500 | $249.96 |
| 2026-06-04 | John Kozarich | Independent Chairperson | Other Acquisition | +836 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:07 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
利干德制药 讨论区 0 条评论